Psilocybin mushrooms are also known as magic mushrooms. Psilocybin is a psychoactive
compound present in some species of mushrooms. It works on a specific subtype of serotonin
receptors in the brain, responsible for mood changes, perception, and cognitive function.
People are interested in psychedelics as they help in treating a range of mental health
conditions, such as anxiety, depression, PSTD, and end-of-life distress. Moreover, it shows
positive therapeutic outcomes in a controlled setting. In this article, we'll explore the diverse
landscape of the psychedelic industry and its effect on mental health.

Research in the Psychedelic Industry

The research on psilocybin started in 1940 as psychedelic medicine to treat various mental conditions like depression and alcohol use disorders. All research was suddenly stopped in 1970 when it was declared a Schedule I drug and became illegal.

However, Benjamin Lewis, MD, director of the Ketamin-Assisted Psychotherapy Clinic at the University of Utah Health, started speaking about psychedelics. He says Classic psychedelics like LSD don’t have negative potentials like other drugs, cocaine, alcohol, nicotine and opioids.

A recent study by John Hopkins shows that psychedelic treatment with psilocybin helps in treating depressive disorder symptoms in patients in a month. Some of these studies have shown psilocybin as a treatment for primary depressive disorder and treatment-resistant depression.

The Effect of Psilocybin on Mental Health

When taken under the supervision of a therapist, in a controlled setting, psilocybin present in (Psilocybin mushrooms) can cause self-described spiritual experiences, resulting in positive changes in an individual. In short, the compound from magic mushrooms increases the personality quality of openness, which includes imagination, sensitivity, and appreciation of others and their viewpoints.

This change is found in individuals who take psilocybin, which connects the chemical ability of cognitive function to increase neuroplasticity and the capability to form new connections. The use of psilocybin in the psychedelic industry can induce neuroplasticity.

The Working of Psychedelic Therapy

Psychedelic therapy is also known as psychedelic-assisted psychotherapy (PAP). It is a type of psychiatric practice that includes taking a psychedelic substance as a part of psychotherapeutic treatment. In therapy, the use of psychedelics is usually combined with talk therapy.

A range of consciousness-altering psychedelic drugs are presently used for clinical or non-clinical research therapeutic purposes. These are derived from plants like psilocybin mushrooms, magic mushrooms, ibogaine, ayahuasca, and peyote. Some more are MDMA, ketamine, LSD and other chemical compounds.

Most importantly, Indigenous people have used psychedelics in therapeutic for years, where this therapy is new in Western clinics. The main reason behind its widespread use with the enormous legalization of some psychedelic substances is the increase in mental health diseases.

The Use of Psychedelics in the Psychedelic Industry

Ketamine

It is the most-studied psychedelic drug for treating mental health diseases. The minimum doses of ketamine showed benefits in various trials, discovering its ability to treat depression. However, its effects are short-lived. For individuals suffering from severe depression, for example, research shows positive improvements after treatment, and the results last six to eight weeks on average rate.

These outcomes have led to the production of a medicine called Spravato. It’s a nasal spray with an active ketamine ingredient. The best part is that intravenous ketamine intake is considered to be more effective and inexpensive.

MDMA

Multiple phase 2 clinical trials have shown that MDMA can help in treating post-traumatic stress disorder (PSTD) for up to four years. Researchers have also finished the phase 3 trial to determine if MDMA-assisted therapy for PSTD works better than current treatments.

The results were amazing. Among ninety individuals with severe post-traumatic stress disorder (PSTD), sixty-seven are thoroughly right after three treatments. And the remaining eighty-eight per cent have just a few symptoms of PSTD. The trial sponsor, the Multidisciplinary Association for Psychedelic Studies, says these positive results make way for Food and Drug Administration (FDA) approval soon.

LSD

LSD, a long-lasting, potent psychedelic that’s known to be the prototype for therapeutic psychedelics, has helped to treat alcohol use disorder and anxiety in individuals suffering from a terminal illness.

Conclusion

According to research and clinical trials, psilocybin mushrooms have shown positive results in treating mental health diseases. But remember that magic mushrooms must be used after consulting with a professional therapist. Avoid using alone, as you may see severe consequences without a doctor’s permission.